Saturday 17 October 2026
Export NEPTF’s income statement to Excel — free account
Neptune Wellness Solutions Inc.
NEPTF Healthcare Drug Manufacturers Specialty & Generic
Revenue growth for five consecutive years, operating cash flow growth for five.
0.00
0.00
NaN
Follow NEPTF
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 1,204.00 | 980.00 | 3,178.00 | 3,444.00 | 1,344.00 | 490.00 | 9.22 | 0.36 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | 2,142.00 | 3,416.00 | 7,196.00 | 9,198.00 | 5,012.00 | 5,040.00 | 785.54 | 41.60 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 139 | — | 61 | 74 | 165 | 127 | 161 | 50 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.35 | 0.25 | 0.13 | 0.28 | 0.30 | 1.05 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 17 | 32 | 22 | 19 | 22 | 35 | 49 | 53 | ||||
| Gross margin, % | — | — | 17.94 | 24.03 | 22.88 | 31.15 | (6.22) | (77.33) | (15.44) | (4.70) | |||||
| EBT | — | — | (10) | 2 | 6 | (18) | (42) | (128) | (84) | (89) | |||||
| EBT margin, % | — | — | (58.06) | 6.61 | 27.85 | (94.19) | (190.22) | (360.85) | (173.01) | (168.78) | |||||
| Net income | — | — | (6) | 5 | 7 | (18) | (46) | (124) | (84) | (89) | |||||
| Depreciation | — | — | 2 | 3 | 3 | 2 | 6 | 19 | 6 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 14.59 | 383.79 | 327.33 | 345.83 | 408.78 | 404.62 | 178.18 | ||||
| Earnings | — | — | (0.08) | 1.94 | 237.76 | (307.69) | (713.29) | (1,454.54) | (621.60) | (204.80) | |||||
| Cash flow | — | — | 0.00 | 1.91 | (105.32) | (109.20) | (367.49) | (654.11) | (450.63) | (96.73) | |||||
| Capex | — | — | 0.00 | 0.00 | 527.88 | (121.74) | (166.80) | (80.75) | (19.66) | (2.58) | |||||
| Free cash flow | — | — | 0.00 | 1.91 | 422.56 | (230.95) | (534.29) | (734.86) | (470.30) | (99.31) | |||||
| Book value | — | — | 0.00 | 21.52 | 1,201.31 | 923.84 | 1,679.34 | 1,588.28 | 504.46 | (93.33) | |||||
| Shares, m | — | — | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 25.26 | 70.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | 4.14 | 2.26 | 6.27 | 13.73 | 4.74 | 4.49 | 0.77 | 0.12 | |||||
| P/B | — | — | 1.50 | 1.47 | 4.08 | 4.86 | 0.98 | 1.15 | 0.62 | 0.00 | |||||
| EV/Sales | — | — | 4.90 | 2.61 | 6.62 | 13.48 | 4.32 | 3.12 | 0.83 | 0.52 | |||||
| EV/FCF | — | — | (9.31) | (28.36) | (71.85) | (19.10) | (2.80) | (1.74) | (0.72) | (0.89) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (9) | 4 | (6) | (6) | (24) | (57) | (54) | (29) | ||||
| Capex | — | — | (1) | (4) | 30 | (7) | (11) | (7) | (2) | (1) | |||||
| Free cash flow | — | — | (9) | 4 | 24 | (13) | (34) | (64) | (57) | (29) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 19 | 19 | 21 | 4 | 16 | 55 | 7 | (17) | ||||
| Total debt | — | — | 21 | 18 | 4 | 3 | 3 | 11 | 12 | 23 | |||||
| Net debt | — | — | 11 | 6 | (17) | (5) | (10) | (48) | 3 | 21 | |||||
| Shareholders’ equity | — | — | 41 | 48 | 68 | 53 | 108 | 138 | 61 | (28) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (7.07) | 5.80 | 17.04 | (24.26) | (46.78) | (78.49) | (51.37) | (88.99) | ||||
| ROIC | — | — | 0.00 | 0.00 | 1.13 | (22.78) | (73.94) | (91.71) | (86.11) | 0.00 | |||||
| ROE | — | — | (12.46) | 10.76 | 23.70 | (29.43) | (57.00) | (100.33) | (75.58) | (363.37) | |||||
Negative figures in brackets.
Fiscal years to Mar 2023 · latest quarter Dec 2023
Charts ten years each
Neptune Wellness Solutions Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AKAN Akanda Corp. | $3.5M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| PRFX PainReform Ltd. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| IMCC IM Cannabis Corp. | $2.2M | — (loss-making) | — (loss-making) | −40.28% (below 0%: shrinking) | n/m | −266.81% (below 0%: shrinking) | 19.83% | (27.54%) | Compare |
| NEPTF Neptune Wellness Solutions Inc. | $1.6M | — (loss-making) | — (loss-making) | −37.75% (below 0%: shrinking) | n/m | +53.44% (above 0%: growing) | 13.62% | (232.88%) | |
| PTPI Petros Pharmaceuticals, Inc. | $1.0M | — (loss-making) | — (loss-making) | +1,070.55% (above 0%: growing) | n/m | +71.27% (above 0%: growing) | 73.82% | 0.00% | Compare |
| SBFM Sunshine Biopharma, Inc. | $990.0K | — (loss-making) | — (loss-making) | −1.56% (below 0%: shrinking) | n/m | +49.38% (above 0%: growing) | 26.20% | (17.41%) | Compare |
| LSDIF Lucy Scientific Discovery Inc. | $900.0K | — (loss-making) | — | — | n/m | −493.98% (below 0%: shrinking) | 59.79% | (8,891.75%) | Compare |
| SXTC China SXT Pharmaceuticals, Inc. | $710.0K | — (loss-making) | — (loss-making) | −16.76% (below 0%: shrinking) | +92.67% (above 0%: growing) | −107.59% (below 0%: shrinking) | 44.09% | 0.00% | Compare |
| Median of peers | $1.6M | — | — | −1.56% | — | −29.11% | 35.15% | (8.70%) |
Neptune Wellness Solutions Inc. (NEPTF) key facts
- Neptune Wellness Solutions Inc. (NEPTF) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector.
- Return on equity was −363.4% and debt-to-equity -0.50.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −27.25 (distress zone) for fiscal 2023.